TY - JOUR T1 - Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by <sup>18</sup>F-FDG Small-Animal PET JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 129 LP - 134 DO - 10.2967/jnumed.106.038836 VL - 49 IS - 1 AU - Jeffrey R. Tseng AU - Keon Wook Kang AU - Mangal Dandekar AU - Shahriar Yaghoubi AU - Joseph H. Lee AU - James G. Christensen AU - Stephen Muir AU - Patrick W. Vincent AU - Neil R. Michaud AU - Sanjiv S. Gambhir Y1 - 2008/01/01 UR - http://jnm.snmjournals.org/content/49/1/129.abstract N2 - The purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody against c-Met, in a subcutaneous U87 MG xenograft mouse model using 18F-FDG small-animal PET. Methods: CE-355621 or control vehicle was administered intraperitoneally into nude mice (drug-treated group, n = 12; control group, n = 14) with U87 MG subcutaneous tumor xenografts. Drug efficacy was evaluated over 2 wk using 18F-FDG small-animal PET and compared with tumor volume growth curves. Results: The maximum %ID/g (percentage injected dose per gram of tissue) of 18F-FDG accumulation in mice treated with CE-355621 remained essentially unchanged over 2 wk, whereas the %ID/g of the control tumors increased 66% compared with the baseline. Significant inhibition of 18F-FDG accumulation was seen 3 d after drug treatment, which was earlier than the inhibition of tumor volume growth seen at 7 d after drug treatment. Conclusion: CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits 18F-FDG accumulation earlier than tumor volume changes in a mouse xenograft model. These results support the use of 18F-FDG PET to assess early tumor response for CE-355621. ER -